search
Back to results

Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Alogliptin and voglibose
Alogliptin and voglibose
Voglibose
Sponsored by
Takeda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes Mellitus - Type 2, Diabetes Mellitus, Drug Therapy

Eligibility Criteria

33 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Had been receiving a stable dose and regimen of an α-glucosidase inhibitor for the last 4 weeks or longer before the start of the screening phase (Week -8) and during the screening phase.
  • Had a glycosylated hemoglobin (HbA1c) value of 6.5% or more and below 10.0% 4 weeks after the start of the screening phase (Week -4).
  • Had HbA1c differences within 10.0% at the start of the screening phase (Week -8) and 4 weeks after the start of the screening phase (Week -4) from the HbA1c value at the start of the screening phase.
  • Was receiving a specific diet therapy and an exercise therapy (if any) for the last 4 weeks or longer before the start of the screening phase (Week -8).

Exclusion Criteria:

  • Had received any antidiabetic drug other than α-glucosidase inhibitors within the last 4 weeks before the start of the screening phase (Week -8) or during the screening phase.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Experimental

    Experimental

    Arm Label

    Voglibose 0.2 mg TID

    Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID

    Alogliptin 25 mg QD and Voglibose 0.2 mg TID

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change From Baseline in Glycosylated Hemoglobin (Week 12).
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.

    Secondary Outcome Measures

    Change From Baseline in Glycosylated Hemoglobin (Week 2).
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.
    Change From Baseline in Glycosylated Hemoglobin (Week 4).
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.
    Change From Baseline in Glycosylated Hemoglobin (Week 8).
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.
    Change From Baseline in Fasting Plasma Glucose (Week 2).
    The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.
    Change From Baseline in Fasting Plasma Glucose (Week 4).
    The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
    Change From Baseline in Fasting Plasma Glucose (Week 8).
    The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
    Change From Baseline in Fasting Plasma Glucose (Week 12).
    The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline.
    Change From Baseline in Fasting C-peptide (Week 2).
    The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline.
    Change From Baseline in Fasting C-peptide (Week 4).
    The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline.
    Change From Baseline in Fasting C-peptide (Week 8).
    The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline.
    Change From Baseline in Fasting C-peptide (Week 12).
    The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline.
    Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value).
    The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)).
    The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2).
    The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2).
    The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).
    The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.

    Full Information

    First Posted
    December 17, 2010
    Last Updated
    February 1, 2012
    Sponsor
    Takeda
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01263483
    Brief Title
    Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
    Official Title
    A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2012
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2007 (undefined)
    Primary Completion Date
    April 2008 (Actual)
    Study Completion Date
    April 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Takeda

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with an α-glucosidase inhibitor taken three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
    Detailed Description
    Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus. Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes. In Japan, α-glucosidase inhibitors are widely used as a first-line treatment for type 2 diabetes mellitus. Because alogliptin has a different mechanism of action compared to α-glucosidase inhibitors, the study evaluated the efficacy and safety of alogliptin combined with an α-glucosidase inhibitor in type 2 diabetic patients with uncontrolled blood glucose while taking a α-glucosidase inhibitor and receiving diet and/or exercise therapies. To evaluate the long-term safety and efficacy of the concomitant use of alogliptin and an α-glucosidase inhibitor, subjects who participated in the present study could enter a long-term extension study SYR-322/OCT-003 (NCT01263509) that was planned separately.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus
    Keywords
    Diabetes Mellitus - Type 2, Diabetes Mellitus, Drug Therapy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    230 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Voglibose 0.2 mg TID
    Arm Type
    Active Comparator
    Arm Title
    Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
    Arm Type
    Experimental
    Arm Title
    Alogliptin 25 mg QD and Voglibose 0.2 mg TID
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Alogliptin and voglibose
    Other Intervention Name(s)
    SYR-322, BASEN®, Voglibose
    Intervention Description
    Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Alogliptin and voglibose
    Other Intervention Name(s)
    SYR-322, BASEN®, Voglibose
    Intervention Description
    Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Voglibose
    Other Intervention Name(s)
    BASEN®
    Intervention Description
    Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
    Primary Outcome Measure Information:
    Title
    Change From Baseline in Glycosylated Hemoglobin (Week 12).
    Description
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.
    Time Frame
    Baseline and Week 12.
    Secondary Outcome Measure Information:
    Title
    Change From Baseline in Glycosylated Hemoglobin (Week 2).
    Description
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.
    Time Frame
    Baseline and Week 2.
    Title
    Change From Baseline in Glycosylated Hemoglobin (Week 4).
    Description
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.
    Time Frame
    Baseline and Week 4.
    Title
    Change From Baseline in Glycosylated Hemoglobin (Week 8).
    Description
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.
    Time Frame
    Baseline and Week 8.
    Title
    Change From Baseline in Fasting Plasma Glucose (Week 2).
    Description
    The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.
    Time Frame
    Baseline and Week 2
    Title
    Change From Baseline in Fasting Plasma Glucose (Week 4).
    Description
    The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
    Time Frame
    Baseline and Week 4.
    Title
    Change From Baseline in Fasting Plasma Glucose (Week 8).
    Description
    The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
    Time Frame
    Baseline and Week 8.
    Title
    Change From Baseline in Fasting Plasma Glucose (Week 12).
    Description
    The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline.
    Time Frame
    Baseline and Week 12.
    Title
    Change From Baseline in Fasting C-peptide (Week 2).
    Description
    The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline.
    Time Frame
    Baseline and Week 2.
    Title
    Change From Baseline in Fasting C-peptide (Week 4).
    Description
    The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline.
    Time Frame
    Baseline and Week 4.
    Title
    Change From Baseline in Fasting C-peptide (Week 8).
    Description
    The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline.
    Time Frame
    Baseline and Week 8.
    Title
    Change From Baseline in Fasting C-peptide (Week 12).
    Description
    The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline.
    Time Frame
    Baseline and Week 12.
    Title
    Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value).
    Description
    The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Time Frame
    Baseline and Week 12.
    Title
    Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)).
    Description
    The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Time Frame
    Baseline and Week 12.
    Title
    Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2).
    Description
    The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Time Frame
    Baseline and Week 12
    Title
    Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2).
    Description
    The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Time Frame
    Baseline and Week 12.
    Title
    Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).
    Description
    The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
    Time Frame
    Baseline and Week 12

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    33 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Had been receiving a stable dose and regimen of an α-glucosidase inhibitor for the last 4 weeks or longer before the start of the screening phase (Week -8) and during the screening phase. Had a glycosylated hemoglobin (HbA1c) value of 6.5% or more and below 10.0% 4 weeks after the start of the screening phase (Week -4). Had HbA1c differences within 10.0% at the start of the screening phase (Week -8) and 4 weeks after the start of the screening phase (Week -4) from the HbA1c value at the start of the screening phase. Was receiving a specific diet therapy and an exercise therapy (if any) for the last 4 weeks or longer before the start of the screening phase (Week -8). Exclusion Criteria: Had received any antidiabetic drug other than α-glucosidase inhibitors within the last 4 weeks before the start of the screening phase (Week -8) or during the screening phase.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Professor, Department of Medicine
    Organizational Affiliation
    Kawasaki Medical School
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    22106975
    Citation
    Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011 Nov;27 Suppl 3:21-9. doi: 10.1185/03007995.2011.614936.
    Results Reference
    derived

    Learn more about this trial

    Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

    We'll reach out to this number within 24 hrs